Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting

Press/Media: Press / Media

PeriodMay 31 2019 → Jun 1 2019

Media coverage

13

Media coverage

  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    CountryJordan
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletYahoo! Finance
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletTMC Net
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletMorningstar.com
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletStocksNewsFeed.com
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletEuroInvestor
    CountryDenmark
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletMarketScreener.com
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel(R) Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletPredictWallStreet
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletPrimeNewswire (Top News)
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletPrimeNewswire (Top News)
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society ...
    Media name/outletEIN Presswire
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletGlobeNewswire
    CountryUnited States
    Date6/1/19
    PersonsMissak Haigentz
  • TitleAtara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
    Media name/outletGlobal Banking & Finance Review
    CountryUnited Kingdom
    Date5/31/19
    PersonsMissak Haigentz